JP6462582B2 - がんの治療のための方法および組成物 - Google Patents

がんの治療のための方法および組成物 Download PDF

Info

Publication number
JP6462582B2
JP6462582B2 JP2015545886A JP2015545886A JP6462582B2 JP 6462582 B2 JP6462582 B2 JP 6462582B2 JP 2015545886 A JP2015545886 A JP 2015545886A JP 2015545886 A JP2015545886 A JP 2015545886A JP 6462582 B2 JP6462582 B2 JP 6462582B2
Authority
JP
Japan
Prior art keywords
patients
rigosatib
treatment
mds
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501884A (ja
JP2016501884A5 (https=
Inventor
マノジ・マニアール
アズラ・ラザ
フランソワ・ウィルヘルム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of JP2016501884A publication Critical patent/JP2016501884A/ja
Publication of JP2016501884A5 publication Critical patent/JP2016501884A5/ja
Application granted granted Critical
Publication of JP6462582B2 publication Critical patent/JP6462582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015545886A 2012-12-07 2013-12-06 がんの治療のための方法および組成物 Active JP6462582B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734933P 2012-12-07 2012-12-07
US61/734,933 2012-12-07
US201361826973P 2013-05-23 2013-05-23
US61/826,973 2013-05-23
PCT/US2013/073667 WO2014089483A1 (en) 2012-12-07 2013-12-06 Methods and compositions for treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016501884A JP2016501884A (ja) 2016-01-21
JP2016501884A5 JP2016501884A5 (https=) 2017-01-12
JP6462582B2 true JP6462582B2 (ja) 2019-01-30

Family

ID=50884042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545886A Active JP6462582B2 (ja) 2012-12-07 2013-12-06 がんの治療のための方法および組成物

Country Status (5)

Country Link
US (1) US10576050B2 (https=)
EP (1) EP2928456B1 (https=)
JP (1) JP6462582B2 (https=)
ES (1) ES2864681T3 (https=)
WO (1) WO2014089483A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3004387A4 (en) * 2013-05-31 2017-04-12 Onconova Therapeutics, Inc. Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders
US11382877B2 (en) 2017-04-13 2022-07-12 Onconova Therapeutics, Inc. Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US12156856B2 (en) * 2017-04-13 2024-12-03 Traws Pharma, Inc. Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
AR109503A1 (es) * 2017-04-13 2018-12-19 Onconova Therapeutics Inc Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento
CA3228644A1 (en) * 2021-08-12 2023-02-16 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548553B2 (en) 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
CN1163480C (zh) 1997-10-03 2004-08-25 坦普尔大学 苯乙烯砜抗癌剂
US6201154B1 (en) 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
US6762207B1 (en) 1999-04-02 2004-07-13 Temple University - Of The Commonwealth System Of Higher Education (E)-styryl sulfone anticancer agents
US6541475B2 (en) 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
AU2001296677A1 (en) 2000-10-05 2002-04-15 Temple University - Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
JP2004521126A (ja) 2001-02-27 2004-07-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
JP4982364B2 (ja) 2004-07-19 2012-07-25 オンコノバ セラピューティクス インコーポレイテッド （ｅ）−２，６−ジアルキルオキシスチリル４−置換ベンジルスルフォン非経口用投与用製剤
US8476320B2 (en) 2007-01-16 2013-07-02 Onconova Therapeutics, Inc Formulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfones
KR101707669B1 (ko) * 2008-04-17 2017-02-16 더 존스 홉킨스 유니버시티 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
CN102438588B (zh) * 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators

Also Published As

Publication number Publication date
JP2016501884A (ja) 2016-01-21
US10576050B2 (en) 2020-03-03
ES2864681T3 (es) 2021-10-14
EP2928456A1 (en) 2015-10-14
EP2928456B1 (en) 2021-02-03
WO2014089483A1 (en) 2014-06-12
EP2928456A4 (en) 2016-08-24
US20150313859A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
US20240342199A1 (en) Combination therapies targeting mitochondria for cancer therapy
KR20230148208A (ko) 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
JP6462582B2 (ja) がんの治療のための方法および組成物
BR112020022148A2 (pt) Métodos de tratamento de câncer
AU2023202746A1 (en) Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
JP7762796B2 (ja) Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
EP3407887A1 (en) Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor
KR102643626B1 (ko) 향상된 안정성 및 생체이용률을 갖는 (ｅ)-2,4,6-트리메톡시스티릴-3-[(카복시메틸)아미노]-4-메톡시벤질설폰의 제형
EP4665325A1 (en) Compositions and methods of using eflornithine
US20220362357A1 (en) Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
HK40040601B (en) (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone for use in a method of treating conditions mediated by abnormal cell proliferation
HK40040601A (en) (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone for use in a method of treating conditions mediated by abnormal cell proliferation
EA039621B1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
HK40007956A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
NZ789582A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
HK40022425A (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
HK40022425B (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181227

R150 Certificate of patent or registration of utility model

Ref document number: 6462582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250